Johnson & Johnson MedTech achieved a major milestone where the Temporary MCS with a microaxial flow pump in AMI-STEMI cardiogenic shock is now a Class IIa recommendation in the 2026 ESC Heart Failure Guidelines.
Published
Signal category
Legal & Regulatory
Quote
“A major milestone achieved: 🏆 Temporary MCS with a microaxial flow pump in AMI-STEMI cardiogenic shock is now a Class IIa recommendation in the 2026 ESC Heart Failure Guidelines.”
— Stefan Dietz|Johnson & Johnson MedTech team
Company
- Industry
- Hospitals and Health Care
- Location
- New Brunswick, US
- Company size
- 38,074 employees
At Johnson & Johnson MedTech, we are working to solve the world’s most pressing healthcare challenges through innovations at the intersection of biology and technology. With deep expertise in surgery, orthopaedics, cardiovascular, and vision, we design healthcare solutions that are smarter, less invasive and more personalized. We are developing the next generation of med tech solutions to tackle the most pervasive and complex health challenges for people around the world. Community Guidelines: http://www.jnj.com/social-media-community-guidelines